Skip to main content
    T

    The Joint Corp (JYNT)

    Official site

    HEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ

    $6.66
    -0.28 (-4.03%)

    Market Cap: $95.00M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    The Joint Corp (JYNT) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    The Joint (JYNT) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, The Joint reported EPS of $0.10, below the $0.11 estimate. It beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    58%(21/36)
    Avg Surprise
    +65.89%

    Upcoming Estimates

    Reports Mar 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.08
    Range$0.00 - $0.15
    6 analysts
    Revenue Consensus
    $14.76M
    Range$13.08M - $16.26M
    6 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.18
    Range$0.18 - $0.18
    1 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.19-5.3%
    60d ago$0.19-5.3%
    30d ago$0.20-10.0%
    7d ago$0.20-10.0%
    Current$0.18
    Revenue Consensus
    $14.03M
    Range$13.41M - $14.77M
    3 analysts

    Next Report

    JYNT has an expected report date of Mar 10, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 33.3% above the $0.06 reported for the quarter ended Dec 31, 2025.

    JYNT Earnings Call

    The latest JYNT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 36 quarters below that had an estimate, JYNT beat 21, missed 14 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $13.55M, up 1.3% from $13.38M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.10$0.11$0.03 - $0.12-9.09%Miss-23.1%30 up, 1 downNov 5, 2026$13.55M
    Jun 30, 2026-$0.01$0.11-$0.02 - $0.13-109.09%MissN/A40 up, 1 downAug 6, 2026$15.18M
    Mar 31, 2026$0.08$0.03-$0.02 - $0.09+166.67%BeatN/A40 up, 0 downMay 7, 2026$14.82M
    Dec 31, 2025$0.06$0.04$0.02 - $0.05+50.00%Beat-63.7%30 up, 0 downMar 12, 2026$15.17M
    Sep 30, 2025$0.13$0.02-$0.06 - $0.08+550.00%Beat+160.0%40 up, 0 downNov 6, 2025$13.38M
    Jun 30, 2025-$0.06-$0.07-$0.11 - $0.06+14.29%BeatN/A40 up, 0 downAug 7, 2025$13.27M
    Mar 31, 2025-$0.03$0.00-$0.05 - $0.03-809.09%Miss-133.3%30 up, 0 downMay 8, 2025$13.08M
    Dec 31, 2024$0.17$0.02$0.00 - $0.03N/AN/AN/A20 up, 1 downMar 13, 2025$14.71M
    Sep 30, 2024$0.05-$0.01-$0.05 - $0.08+600.00%BeatN/A50 up, 0 downNov 7, 2024$12.65M
    Jun 30, 2024-$0.13-$0.01-$0.07 - $0.03N/AN/AN/A50 up, 0 downAug 8, 2024$12.61M
    Mar 31, 2024$0.09-$0.01-$0.05 - $0.02+1000.00%BeatN/A50 up, 0 downMay 2, 2024$12.18M
    Dec 31, 2023-$0.75$0.01-$0.03 - $0.04N/AN/A-1975.0%50 up, 0 downMar 7, 2024N/A
    Sep 30, 2023-$0.05$0.01$0.00 - $0.06-600.00%Miss-200.0%50 up, 0 downNov 9, 2023$29.47M
    Jun 30, 2023-$0.01$0.01-$0.01 - $0.03-200.00%Miss-133.3%30 up, 0 downSep 13, 2023$29.31M
    Mar 31, 2023-$0.03-$0.01-$0.04 - $0.01-200.00%MissN/A50 up, 0 downMay 4, 2023$28.30M
    Dec 31, 2022$0.04$0.08$0.05 - $0.11-50.00%Miss+300.0%60 up, 0 downMar 9, 2023N/A
    Sep 30, 2022$0.05$0.06$0.04 - $0.07-16.67%Miss-61.5%60 up, 0 downNov 3, 2022$26.45M
    Jun 30, 2022$0.03-$0.01-$0.06 - $0.05+400.00%Beat-83.3%60 up, 0 downAug 4, 2022$24.89M
    Mar 31, 2022-$0.01$0.04$0.02 - $0.06-125.00%Miss-106.3%60 up, 1 downMay 5, 2022$22.24M
    Dec 31, 2021$0.01$0.06$0.02 - $0.08-83.33%Miss-98.6%61 up, 0 downFeb 24, 2022$21.25M
    Sep 30, 2021$0.13$0.03$0.02 - $0.10+333.33%Beat+18.2%6N/ANov 4, 2021$20.99M
    Jun 30, 2021$0.18$0.06$0.04 - $0.08+200.00%Beat+1700.0%6N/AAug 5, 2021$20.22M
    Mar 31, 2021$0.16$0.05$0.03 - $0.07+220.00%Beat+166.7%5N/AMay 6, 2021$17.55M
    Dec 31, 2020$0.72$0.14$0.12 - $0.17+414.29%Beat+700.0%6N/AMar 4, 2021$17.04M
    Sep 30, 2020$0.11-$0.01-$0.04 - $0.07N/AN/A+175.0%6N/ANov 5, 2020$15.41M
    Jun 30, 2020$0.01-$0.13-$0.22 - -$0.01+107.69%Beat-66.7%6N/AAug 6, 2020$12.59M
    Mar 31, 2020$0.06$0.07$0.03 - $0.09-14.29%Miss-14.3%6N/AMay 7, 2020$13.64M
    Dec 31, 2019$0.09$0.07$0.06 - $0.08+28.57%Beat+50.0%6N/AMar 5, 2020$13.88M
    Sep 30, 2019$0.04$0.03$0.01 - $0.05+33.33%Beat+300.0%6N/ANov 7, 2019$12.73M
    Jun 30, 2019$0.03$0.04$0.01 - $0.08-25.00%Miss+200.0%6N/AAug 8, 2019$11.17M
    Mar 31, 2019$0.07$0.03$0.00 - $0.04+133.33%BeatN/A5N/AMay 9, 2019$10.68M
    Dec 31, 2018$0.06$0.03$0.02 - $0.06+100.00%BeatN/A5N/AMar 7, 2019$9.97M
    Sep 30, 2018$0.01$0.01$0.00 - $0.020.00%In lineN/A4N/ANov 8, 2018$9.24M
    Jun 30, 2018$0.01-$0.01-$0.03 - $0.01+200.00%BeatN/A4N/AAug 9, 2018$8.80M
    Mar 31, 2018-$0.03-$0.02-$0.03 - -$0.02-50.00%MissN/A4N/AMay 10, 2018$8.65M
    Dec 31, 2017-$0.02-$0.03-$0.03 - -$0.03+33.33%BeatN/A3N/AMar 8, 2018$25.93M
    Sep 30, 2017-$0.03-$0.07N/A+57.14%BeatN/AN/AN/ANov 9, 2017$6.54M
    Jun 30, 2017-$0.08-$0.10N/A+20.00%BeatN/AN/AN/AAug 10, 2017$6.00M
    Mar 31, 2017-$0.13-$0.12N/A-8.33%MissN/AN/AN/AMay 11, 2017$11.37M
    Dec 31, 2016-$0.18-$0.20N/A+10.00%BeatN/AN/AN/AMar 9, 2017$5.78M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.10, down 42.9% from the year before. It was -$0.93 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.10-42.9%
    Dec 31, 2024$0.18N/A
    Dec 31, 2023-$0.84-863.6%
    Dec 31, 2022$0.11-77.1%
    Dec 31, 2021$0.48-46.7%
    Dec 31, 2020$0.90+291.3%
    Dec 31, 2019$0.23+360.0%
    Dec 31, 2018$0.05N/A
    Dec 31, 2017-$0.26N/A
    Dec 31, 2016-$0.93N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,200 words across 5 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,1655
    2026Q2Jun 30, 20264,7116
    2026Q1Mar 31, 20265,0097
    2025Q4Dec 31, 20256,1588
    2025Q3Sep 30, 20254,9758
    2025Q2Jun 30, 20255,3048
    2025Q1Mar 31, 20254,1238
    2024Q3Sep 30, 20244,1126

    2026Q3 Earnings Call

    Opening remarks

    Richard Land Conference Call Host Thank you, Danielle, and good afternoon, everyone. Joining us on the call today are President and CEO Sanjiv Razdan and CFO Scott Baumann. Please note we are using a slide presentation that can be found on The Joint's investor relations website. This afternoon, The Joint Corp. issued a press release for the third quarter ended September 30, 2026. The release is available on the company's website. Please be advised that today's discussion, including any financial and related guidance, will include forward-looking statements as defined by securities laws. These statements are based on information currently available to us and involve risks and uncertainties that could cause actual future results, performance, and business prospects and opportunities to differ materially from those expressed in or implied by these statements. Some important factors that could cause such differences are discussed in the Risk Factors section of The Joint Corp.'s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements are made, and the company assumes no obligation to update them, except to the extent required by applicable securities laws. Management uses non-GAAP financial measures such as EBITDA, adjusted EBITDA, and free cash flow. A description of these measures is included in the press release issued earlier this afternoon, and reconciliations to the most directly comparable GAAP measures are included in the appendix to the presentation and press release, both available in the Investors tab of our website. With that, I will now turn the call over to Sanjiv Razdan. Sanjiv, please go ahead.

    Sanjiv Razdan President and CEO Thank you, Richard, and good afternoon, everyone. Our third-quarter results show that the actions we have taken to strengthen patient engagement and reshape our operating model are beginning to work together. We are encouraged by progress in several of our leading patient metrics, while recognizing that the consumer environment continues to weigh on spending and our comparable sales. Our active membership count grew during the quarter as our initiative to win back lapsed patients gained momentum. Patients are also staying with us longer and spending more over the course of their relationship with The Joint, supporting higher patient lifetime value. At the same time, ongoing pressure on consumer spending led to fewer new patients and lower average patient spend per month, which weighed on comp sales. Comp sales were down 1.9% in the third quarter, improving from down 2.8% in the second quarter and down 4.2% in the first quarter. Financially, we continue to see the benefits of our capital-light model, with revenue growth and stronger profitability from continuing operations. Scott will walk through the results in more detail.

    Frequently Asked Questions About JYNT

    When is The Joint's next earnings date?

    The Joint's next earnings report is expected for Mar 10, 2027.

    Did JYNT beat earnings estimates last quarter?

    No. The Joint reported EPS of $0.10 for the quarter ended Sep 30, 2026, below the $0.11 estimate by 9.09%.

    What EPS do analysts expect from JYNT next quarter?

    The consensus EPS estimate for The Joint for the quarter ending Dec 31, 2026 is $0.08 from 6 analysts, with estimates from $0.00 to $0.15.

    How often does JYNT beat earnings estimates?

    The Joint beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate, with an average surprise of +56.71%.